Long-Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Rheumatol. 2025. Epub ahead of print. doi: 10.1093/rheumatology/keaf009
Baraliakos et al. evaluated the long-term safety and efficacy of bimekizumab in axSpA through a 2-year analysis of the BE MOBILE 1 and BE MOBILE 2 studies. Bimekizumab was well tolerated, with a consistent safety profile and no new safety signals. Clinical improvements, including ASAS40 response and MRI remission, were sustained through Wk104.
The study followed patients from the BE MOBILE studies into an open-label extension (BE MOVING), where all received bimekizumab 160mg Q4W. Over two years, more than half achieved ASAS40 response, and inflammatory markers remained suppressed on MRI. The findings reinforce bimekizumab as a viable long-term treatment option for axSpA.
Keywords:
